文献速递造血干细胞移植与细胞治疗白血病

移植后环磷酰胺在HLA相合同胞干细胞移植治疗急性髓系白血病后分离移植物抗宿主病与移植物抗白血病效应

Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia.
PubMed 文献 · Leukemia · 2024-10-31

该研究评估了HLA相合干细胞移植后急性髓系白血病患者中移植物抗宿主病(GVHD)与移植物抗白血病(GVL)效应的关联。标准钙调磷酸酶抑制剂预防组(n=12,653)中,急性GVHD II-IV级和III-IV级、慢性GVHD及广泛性慢性GVHD发生率分别为23.8%、7.5%、37.0%和16.3%,且GVHD与较低复发、较高非复发死亡和较低总生存相关。移植后环磷酰胺(PTCy)组(n=508)GVHD发生率分别为22.8%、6.2%、35.5%和17.7%,但急性GVHD与复发无关联(HR 1.37,P=0.15),慢性GVHD对这些结局无预后价值。

要点

  • 标准预防下急性GVHD II-IV级与较低复发相关(HR 0.85,P=0.002),但非复发死亡升高(HR 1.5,P<0.001)。
  • PTCy后急性GVHD与复发无显著关联(HR 1.37,P=0.15),慢性GVHD对复发、非复发死亡和总生存均无预后价值。
  • PTCy可能分离GVHD与GVL效应,但需进一步研究验证。

核心结论

  • 在当代干细胞移植中,GVHD与GVL效应仍强相关;但采用PTCy后,GVHD与复发减少无关联。

研究设计与样本

  • 回顾性队列研究,纳入接受HLA相合干细胞移植的急性髓系白血病患者,标准钙调磷酸酶抑制剂预防组n=12,653(57%联合体内T细胞去除),PTCy组n=508。

主要发现

  • 标准预防组急性GVHD II-IV级和III-IV级、慢性GVHD、广泛性慢性GVHD发生率分别为23.8%、7.5%、37.0%、16.3%;PTCy组分别为22.8%、6.2%、35.5%、17.7%。
  • 标准预防组急性GVHD II级与较低复发相关(HR 0.85,P=0.002),III-IV级与较低复发相关(HR 0.76,P=0.003);II级与较高非复发死亡相关(HR 1.5,P<0.001),III-IV级与较高非复发死亡相关(HR 6.21,P<0.001);II级与较低总生存相关(HR 1.49,P<0.001),III-IV级与较低总生存相关(HR 6.1,P<0.001)。
  • 标准预防组广泛性慢性GVHD与较低复发相关(HR 0.69,P<0.001),与较高非复发死亡相关(HR 2.83,P<0.001),与较低总生存相关(HR 2.74,P<0.001)。
  • PTCy组急性GVHD与复发无显著关联(HR 1.37,P=0.15),与较高非复发死亡相关(HR 3.34,P<0.001),与较低总生存相关(HR 1.92,P=0.001);慢性GVHD对复发、非复发死亡和总生存均无预后价值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The association of graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effects after allogeneic stem-cell transplantation (SCT) is well-established but was not confirmed in the modern era and following post-transplant cyclophosphamide (PTCy). We assessed GVHD/ GVL association in AML patients following HLA-matched SCT with standard calcineurin-based (n = 12,653, 57% with additional in-vivo T-cell depletion) or PTCy-based (n = 508) GVHD prophylaxis. Following standard prophylaxis, acute GVHD grade II-IV and III-IV, chronic GVHD, and extensive chronic GVHD rates were 23.8%, 7.5%, 37.0%, and 16.3%, respectively. Acute GVHD grade II and III-IV were associated with lower relapse [hazard-ratio (HR) 0.85, P = 0.002; HR 0.76, P = 0.003, respectively)], higher non-relapse mortality (NRM) (HR 1.5, P < 0.001; HR 6.21, P < 0.001) and lower overall survival (OS) (HR 1.49, P < 0.001; HR 6.1, P < 0.001). Extensive chronic GVHD predicted lower relapse (HR 0.69, P < 0.001), higher NRM (HR 2.83, P < 0.001), and lower OS (HR 2.74, P < 0.001). Following PTCy, GVHD rates were 22.8%, 6.2%, 35.5%, and 17.7%, respectively. Acute GVHD was not associated with relapse (HR 1.37, P = 0.15) but predicted higher NRM (HR 3.34, P < 0.001) and lower OS (HR 1.92, P = 0.001). Chronic GVHD was not prognostic for these outcomes. In conclusion, GVHD and GVL are strongly associated with contemporary SCT. However, following PTCy, GVHD is not associated with reduced relapse.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Shimoni A, Peczynski C, Labopin M, et al. Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia. Leukemia. 2024. PMID: 39482353. doi:10.1038/s41375-024-02445-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。